New Survey Focused on Access Limitations of Approved Autologous CAR T Therapies Reveals Only 50% of Eligible Cancer Patients Receive Treatment
Increased Patient Demand, Manufacturing Capacity and Time to
- Presentations from UNITY's leadership team and fireside chat with retina expert Robert B. Bhisitkul, M.D., Ph.D., on Wednesday, October 12 from 8:00 a.m. to 9:30 a.m. ET -
SOUTH SAN FRANCISCO, Calif., Oct.
BOTHELL, Wash., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) announces the selection of its novel, broad-spectrum antiviral drug candidate CDI-988 for clinical development as an
BURLINGTON, Mass. and JERUSALEM, Oct. 11, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive
ROCHESTER, Mich., Oct. 11, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on
PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that recent clinical trial and real-world evidence on the efficacy and safety of Translarna™ (ataluren) in patients with nonsense mutation Duchenne muscular
Groundbreaking NAUTILUS study will evaluate the safety and effectiveness of the RNS System to treat generalized epilepsy in patients aged 12 and older
NeuroPace, Inc. (NASDAQ:NPCE), a commercial stage medical device
Sanofi SA (NASDAQ:SNY) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) presented more positive data for their Dupixent product. The companies said new Dupixent data showed…